Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPAG5 antisense RNA 1 (SPAG5-AS1)
- Target
- SPAG5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
SPAG5 antisense RNA 1 (SPAG5-AS1) is a cytoplasmic long non-coding RNA (lncRNA) that regulates the neighboring gene SPAG5 at both transcriptional and post-translational levels. It acts by sponging microRNAs (notably miR-769-5p), thereby modulating the expression of the transcription factor YY1, which in turn upregulates SPAG5. SPAG5-AS1 also binds to the deubiquitinase USP14 to stabilize SPAG5 protein. Functionally, SPAG5-AS1 is implicated in the regulation of cell apoptosis and autophagy, specifically in high-glucose–treated human podocyte models, via the SPAG5/AKT/mTOR signaling pathway. While it indirectly affects pathways and proteins recurrently implicated in cancer biology, including the regulation of the established oncogene SPAG5, SPAG5-AS1 itself is not currently established as a direct therapeutic target or approved biomarker.
02
Mechanism of action
Not directly drug-targeted; mechanism involves: ceRNA activity (sponging miRNAs to control mRNA levels); Protein interaction (binding to deubiquitinase USP14, enhancing stability of the SPAG5 protein); Epigenetic/transcription regulation (regulation of SPAG5 and YY1 expression).
03
Biological functions
Regulation of gene expression (specifically, positive regulation of SPAG5 transcription and protein stability)Acts as a competing endogenous RNA (ceRNA) sponging microRNAs, especially miR-769-5p, to regulate downstream gene expressionModulation of autophagy and apoptosis (in podocyte models), via the SPAG5/AKT/mTOR pathway
04
Disease associations
Potential role in diabetic nephropathy (through involvement in high-glucose-induced podocyte injury)Indirect implications in cancer via regulation of SPAG5, an established oncogene in various tumor types, but no direct evidence that SPAG5-AS1 itself is a cancer driver
05
Safety considerations
None reported; as a non-coding RNA studied primarily in basic molecular biology and disease models, not therapeutically targeted or associated with specific safety concerns
06
Biomarkers
None established for clinical use; has been studied as a regulatory molecule affecting biomarkers such as SPAG5 and YY1 expression in podocyte models
Beyond the preview
Go deeper on SPAG5 antisense RNA 1 (SPAG5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPAG5 antisense RNA 1 (SPAG5-AS1).